Hypoxic tumor microenvironment activates GLI2 via HIF-1α and TGF-β2 to promote chemoresistance in colorectal cancer
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Significance: Colorectal cancer patients often relapse due to resistance to chemotherapy. The tumor microenvironment is known to contribute to tumor aggressiveness and chemoresistance, but the underlying mechanisms remain elusive. In the current study, we have shown that cancer-associated fibroblasts (CAFs) which are often present in the tumor can greatly promote resistance of colorectal cancer cells to chemotherapy. In the low-oxygen condition (hypoxia), CAFs-secreted growth factor TGF-β2 can induce strong expression of GLI2 , a gene that can induce resistance to therapy. As such, therapeutic targeting of TGF-β and GLI2 can be developed into a useful adjuvant to enhance the effect of chemotherapies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“CAF can release TGF-β2 under hypoxia, synergize with HIF-1α, activate GLI2 expression through the non-canonical Hedgehog pathway and promote CRC resistance to 5-FU/oxaliplatin [296].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [296]
Citations
Cites
Adjusting batch effects in microarray expression data using empirical Bayes methods
Johnson, W. E., Li, C., & Rabinovic, A. (2007) · Biostatistics · doi:10.1093/biostatistics/kxj037 · Cited by 8,658
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170 · cited 1×
“(6) performed a comprehensive transcriptome analysis of publicly available gene expression data of CRC patients and identified four consensus molecular subtypes with distinguishing features.”
BackgroundTargeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
Locatelli, F., Fishbane, S., Block, G. A., & Macdougall, I. C. (2017) · American Journal of Nephrology · doi:10.1159/000455166 · Cited by 4,813
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632 · cited 1×
“CAFs are key players in the tumor microenvironment known to secrete compounds that potentiate tumor malignancy (25, 26).”
BackgroundA human colon cancer cell capable of initiating tumour growth in immunodeficient mice
O’Brien, C. A., Pollett, A., Gallinger, S., & Dick, J. E. (2007) · Nature · doi:10.1038/nature05372 · Cited by 4,087
Targeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172 · cited 4×
“While the hypoxic tumors and microenvironment may represent a subpopulation in bulk tumors, the biggest challenge is to develop and improve the predictive tools of patient stratification for targeting hypoxic-related signaling pathways (23).”
BackgroundInfluentialWnt activity defines colon cancer stem cells and is regulated by the microenvironment
Vermeulen, L., De Sousa E Melo, F., van der Heijden, M., Cameron, K., de Jong, J. H., Borovski, T., Tuynman, J. B., Todaro, M., Merz, C., Rodermond, H., et al. (2010) · Nature Cell Biology · doi:10.1038/ncb2048 · Cited by 1,804 · cited 2×
“On the other hand, we did not find that Wnt signaling was crucial in mediating the CAF-enhanced CSC activity in our models, although CAFs have been previously reported to promote the self-renewal activity of CSCs via Wnt pathway (10, 11).”
BackgroundHIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression
Keith, B., Johnson, R. S., & Simon, M. C. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3183 · Cited by 1,693 · cited 1×
“Hypoxia, a critical feature in the tumor microenvironment, has been shown to promote cancer stemness through the hypoxiainducible factors (HIFs) (15, 16).”
BackgroundThe Cancer Stem Cell Niche: How Essential Is the Niche in Regulating Stemness of Tumor Cells?
Plaks, V., Kong, N., & Werb, Z. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2015.02.015 · Cited by 1,557 · cited 1×
“Hypoxia, a critical feature in the tumor microenvironment, has been shown to promote cancer stemness through the hypoxiainducible factors (HIFs) (15, 16).”
BackgroundSu, S., Chen, J., Yao, H., Liu, J., Yu, S., Lao, L., Wang, M., Luo, M., Xing, Y., Chen, F., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.009 · Cited by 1,230
Cited by
Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions
Chen, Z., Han, F., Du, Y., Shi, H., & Zhou, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01332-8 · Cited by 1,612
“HIF-1α and cancer-associated fibroblast-secreted TGF-β signaling synergistically promote GLI family zinc finger 2 (GLI2) expressions through SMAD3, inducing CRC cell stemness and chemoresistance.(368) Upregulated HIF-2α promotes sorafenib resistance in hypoxic HCC cells by activating the TGF-α/EGFR and COX-2 pathways.”
BackgroundExtracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy
Henke, E., Nandigama, R., & Ergün, S. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2019.00160 · Cited by 1,142
“Especially under hypoxic conditions, CAFs produce high levels of TGFβ, which induces stem celllike properties in tumor cells including increased resistance to chemotherapy (Tang et al., 2018).”
BackgroundFiori, M. E., Di Franco, S., Villanova, L., Bianca, P., Stassi, G., & De Maria, R. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0994-2 · Cited by 647
Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape
Wu, Q., You, L., Nepovimova, E., Heger, Z., Wu, W., Kuca, K., & Adam, V. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01292-6 · Cited by 485
Cancer stem cell (CSC) resistance drivers
Najafi, M., Mortezaee, K., & Majidpoor, J. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116781 · Cited by 466
Targeting TGFβ signal transduction for cancer therapy
Liu, S., Ren, J., & ten Dijke, P. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00436-9 · Cited by 413
“In hypoxic TME, CAF-secreted TGFβ2 can cooperate with hypoxia-inducible factor to increase stemness phenotype and induce robust chemotherapy of cancer cells.(150) Radiation-induced TGFβ signaling can activate CAFs in the TME, which enhances the invasiveness of the associated tumor cells via promoting EMT.”
BackgroundSinghal, R., & Shah, Y. M. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.rev120.011188 · Cited by 376
“Hypoxia is associated with increased growth, survival, proliferation, invasion, and metastasis and confers resistance to chemo- and radiotherapies (144, 145).”
BackgroundCorbet, C., Bastien, E., Santiago de Jesus, J. P., Dierge, E., Martherus, R., Vander Linden, C., Doix, B., Degavre, C., Guilbaud, C., Petit, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14262-3 · Cited by 330
Loh, J.-J., & Ma, S. (2024) · Cell Stem Cell · doi:10.1016/j.stem.2024.04.004 · Cited by 314
Pietrobono, S., Gagliardi, S., & Stecca, B. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00556 · Cited by 303
“Indeed, recurrent ovarian tumors are enriched in CSCs that express high levels of GLI2 and components of TGF-β pathway, such as the co-receptor endoglin (CD105).”
BackgroundInfluentialCancer-associated fibroblasts: overview, progress, challenges, and directions
Ping, Q., Yan, R., Cheng, X., Wang, W., Zhong, Y., Hou, Z., Shi, Y., Wang, C., & Li, R. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00318-4 · Cited by 285
The role of hypoxia‐inducible factor 1 in tumor immune evasion
You, L., Wu, W., Wang, X., Fang, L., Adam, V., Nepovimova, E., Wu, Q., & Kuca, K. (2021) · Medicinal Research Reviews · doi:10.1002/med.21771 · Cited by 265
“Hypoxia‐induced HIF‐1 activates the expression of the hedgehog transcription factor GLI2 through the binding of HIF‐1α to the GLI2 promoter, resulting in the GLI2‐dependent resistance of colorectal tumors to chemotherapy.(61) HIF‐1 can induce epithelial‐to‐mesenchymal transition (EMT) and repress the expression of epi…”
BackgroundKumar, V., Vashishta, M., Kong, L., Wu, X., Lu, J. J., Guha, C., & Dwarakanath, B. S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.650772 · Cited by 255
“…TGF-β2 activate the expression GLI2 in CSCs, resulting in increased stemness/dedifferentiation and intrinsic resistance to chemotherapy Tang et al., 2018 5-FU/tirinotecan Intrinsic HH inhibitor (AY9944/GANT61) with 5FU/Trinotecan reduces stem cells marker and colony formation,…”
BackgroundSelf-citationCancer-Associated Fibroblasts: Tumorigenicity and Targeting for Cancer Therapy
Glabman, R. A., Choyke, P. L., & Sato, N. (2022) · Cancers · doi:10.3390/cancers14163906 · Cited by 254
Hedgehog signaling in tissue homeostasis, cancers and targeted therapies
Jing, J., Wu, Z., Wang, J., Luo, G., Lin, H., Fan, Y., & Zhou, C. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01559-5 · Cited by 247
Transforming Growth Factor-β Signaling in Fibrotic Diseases and Cancer-Associated Fibroblasts
Shi, X., Young, C. D., Zhou, H., & Wang, X.-J. (2020) · Biomolecules · doi:10.3390/biom10121666 · Cited by 243
Transforming Growth Factor-β Signaling Pathway in Colorectal Cancer and Its Tumor Microenvironment
Itatani, Y., Kawada, K., & Sakai, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235822 · Cited by 240
Hedgehog/GLI Signaling Pathway: Transduction, Regulation, and Implications for Disease
Sigafoos, A. N., Paradise, B. D., & Fernandez-Zapico, M. E. (2021) · Cancers · doi:10.3390/cancers13143410 · Cited by 239
Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment
Wu, P., Gao, W., Su, M., Nice, E. C., Zhang, W., Lin, J., & Xie, N. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.641469 · Cited by 209
“…in Cell and Developmental Biology | www.frontiersin.org 2 March 2021 | Volume 9 | Article 641469 TGF-β2 secreted by CAFs cooperate with HIF-1α derived from the hypoxic TME to activate the Hedgehog pathway, which promotes cancer cell stemness and resistance to chemotherapy (Tang et al., 2018).”
BackgroundHIF-1α signaling: Essential roles in tumorigenesis and implications in targeted therapies
Zhao, Y., Xing, C., Deng, Y., Ye, C., & Peng, H. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2023.02.039 · Cited by 202
“Recent studies have confirmed that high expression levels of HIF-1a/TGF-b2/GLI2 are closely associated with relapse after chemotherapy in patients.(86) Inhibition of HIF-1a could effectively reverse chemoresistance induced by the TME by blocking TGF-b2/GLI2 signaling, indicating a potential biomarker and therapeutic t…”
BackgroundResultTGF-β Signaling: From Tissue Fibrosis to Tumor Microenvironment
Chung, J. Y.-F., Chan, M. K.-K., Li, J. S.-F., Chan, A. S.-W., Tang, P. C.-T., Leung, K.-T., To, K.-F., Lan, H.-Y., & Tang, P. M.-K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147575 · Cited by 200
“Furthermore, TGF-β2 and hypoxia-inducible factor (HIF1) secreted by CAF can also activate Hedgehog signaling pathway mediator GLI2 to promote cancer cell stemness and chemotherapy resistance in colorectal cancer, consequently [136].”
BackgroundCancer-associated fibroblasts: Origin, function, imaging, and therapeutic targeting
Rimal, R., Desai, P., Daware, R., Hosseinnejad, A., Prakash, J., Lammers, T., & Singh, S. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114504 · Cited by 195
Nallasamy, P., Nimmakayala, R. K., Parte, S., Are, A. C., Batra, S. K., & Ponnusamy, M. P. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01682-x · Cited by 193
TGF-β Signaling and Resistance to Cancer Therapy
Zhang, M., Zhang, Y. Y., Chen, Y., Wang, J., Wang, Q., & Lu, H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.786728 · Cited by 191
“Moreover, hypoxiainducible factor (HIF-1α) and cancer-associated fibroblasts (CAFs)-secreted TGF-β2 converge to activate the expression of hedgehog transcription factor GLI2 in CRC-CSCs, resulting in increased stemness/dedifferentiation and resistance to 5-FU (Tang et al., 2018).”
BackgroundSelf-citationTGF-β, EMT, and resistance to anti-cancer treatment
Wang, X., Eichhorn, P. J. A., & Thiery, J. P. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.10.004 · Cited by 170
The Role of Tumor-Stroma Interactions in Drug Resistance Within Tumor Microenvironment
Ni, Y., Zhou, X., Yang, J., Shi, H., Li, H., Zhao, X., & Ma, X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.637675 · Cited by 168
“Hypoxia-inducible factor (HIF-1α) has been shown to synergize with CAFs paracrine signals, namely TGF-β2, to activate hedgehog transcription factor GLI2 in cancer stem cells (CSCs), leading to enhanced stemness/dedifferentiation and intrinsic resistance to chemotherapy of colorectal cancer (Tang et al., 2018).”
BackgroundTransforming growth factor‐β signaling: Tumorigenesis and targeting for cancer therapy
Ahmadi, A., Najafi, M., Farhood, B., & Mortezaee, K. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27955 · Cited by 165
Wang, S., Su, X., Xu, M., Xiao, X., Li, X., Li, H., Keating, A., & Zhao, R. C. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1220-2 · Cited by 164
Hypoxia in solid tumors: a key promoter of cancer stem cell (CSC) resistance
Najafi, M., Farhood, B., Mortezaee, K., Kharazinejad, E., Majidpoor, J., & Ahadi, R. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-03080-1 · Cited by 163
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Xu, K., Zhan, Y., Yuan, Z., Qiu, Y., Wang, H., Fan, G., Wang, J., Li, W., Cao, Y., Shen, X., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.05.017 · Cited by 160
Jena, B. C., Sarkar, S., Rout, L., & Mandal, M. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.08.002 · Cited by 152
Dysregulated Signalling Pathways Driving Anticancer Drug Resistance
Antoun, N. B., & Chioni, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512222 · Cited by 152
“HIF-1α/TGF-β2/GLI2 signalling is responsible for chemoresistance in CRC cells [246].”
BackgroundMa, Z., Xiang, X., Li, S., Xie, P., Gong, Q., Goh, B.-C., & Wang, L. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.09.011 · Cited by 133
Glycolysis, the sweet appetite of the tumor microenvironment
Kooshan, Z., Cárdenas-Piedra, L., Clements, J. A., & Batra, J. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217156 · Cited by 144
Hypoxia Dictates Metabolic Rewiring of Tumors: Implications for Chemoresistance
Belisario, D. C., Kopecka, J., Pasino, M., Akman, M., De Smaele, E., Donadelli, M., & Riganti, C. (2020) · Cells · doi:10.3390/cells9122598 · Cited by 133
“Recently, an additional mechanism—based on a crosstalk between CAFs and cancer cells—has been described to link chemoresistance and stemness: indeed, the production of TGF-β2, which typically occurs in an acidic TME [81], from CAFs, increases the intra-tumor expression of GLI2 that favors stemness maintenance in colon…”
BackgroundChan, T., Shaked, Y., & Tsai, K. K. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00688 · Cited by 132
Zhong, B., Cheng, B., Huang, X., Xiao, Q., Niu, Z., Chen, Y., Yu, Q., Wang, W., & Wu, X. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04461-6 · Cited by 129
Self-citationWang, W., Tang, Y., Xiao, Q., Lee, W. C., Cheng, B., Niu, Z., Oguz, G., Feng, M., Lee, P. L., Li, B., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24687-4 · Cited by 125
Self-citationCancer-Associated Fibroblasts in the Hypoxic Tumor Microenvironment
Kim, I., Choi, S., Yoo, S., Lee, M., & Kim, I. (2022) · Cancers · doi:10.3390/cancers14143321 · Cited by 118
Jurj, A. M., Ionescu, C., Berindan‐Neagoe, I., & Braicu, C. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02484-1 · Cited by 116
“An increased expression of HIF-1α/TGFβ2/ GLI2 was shown to be related to the risk of recurrence in patients undergoing chemotherapy [216].”
BackgroundSignaling pathways in the regulation of cancer stem cells and associated targeted therapy
Wang, M., & Wu, M. (2022) · MedComm · doi:10.1002/mco2.176 · Cited by 108
Genomic testing, tumor microenvironment and targeted therapy of Hedgehog-related human cancers
Katoh, M. (2019) · Clinical Science · doi:10.1042/cs20180845 · Cited by 107
Chen, J., Jiang, Z., Xu, W., Sun, T., Zhuang, X., Ding, J., & Chen, X. (2020) · Nano Letters · doi:10.1021/acs.nanolett.0c02515 · Cited by 101
Cancer stem cell (a)symmetry & plasticity: Tumorigenesis and therapy relevance
Najafi, M., Mortezaee, K., & Ahadi, R. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.05.076 · Cited by 104
Zhang, J., Fan, J., Zeng, X., Nie, M., Luan, J., Wang, Y., Ju, D., & Yin, K. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.10.022 · Cited by 90
Role of Hypoxic Stress in Regulating Tumor Immunogenicity, Resistance and Plasticity
Terry, S., Zaarour, R. F., Venkatesh, G. H., Francis, A., El‐Sayed, W., Buart, S., Bravo, P. E., Thiery, J., & Chouaïb, S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103044 · Cited by 99
Kao, T.-W., Bai, G.-H., Wang, T.-L., Shih, I.-M., Chuang, C.-M., Lo, C.-L., Tsai, M.-C., Chiu, L.-Y., Lin, C.-C., & Shen, Y.-A. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02724-y · Cited by 89
“Consistently, overexpression of HIFs is associated with resistance to cancer treatment, metastasis, and poor prognosis in patients [7].”
BackgroundFunctional diversity of cancer‐associated fibroblasts in modulating drug resistance
Bu, L., Baba, H., Yasuda, T., Uchihara, T., & Ishimoto, T. (2020) · Cancer Science · doi:10.1111/cas.14578 · Cited by 86
Kim, T. W., & Lee, H.-G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413455 · Cited by 79
Modulation of the tumor microenvironment (TME) by melatonin
Qi, M., & Najafi, M. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174365 · Cited by 85
Ziani, L., Buart, S., Chouaïb, S., & Thiery, J. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1950953 · Cited by 85
“Furthermore, in colorectal cancers, hypoxic CAFs hypersecretion of TGF-β2 can induce strong expression of GLI2 (GLI family zinc finger 2) by cancer stem cells, and consequently promotes resistance to therapy.(38) In mammary tumors, hypoxia also induces a pronounced remodeling of the CAF proteome, favoring endothelial…”
BackgroundZhang, H., Ren, L., Ding, Y., Li, F., Chen, X., Ouyang, Y., Zhang, Y., & Zhang, D. (2019) · The FASEB Journal · doi:10.1096/fj.201802186r · Cited by 82
“Accumulating evidence revealed that TGF-b/Smad2 conferred resistance to therapy of multiple chemotherapydrugs (23, 26, 27).”
BackgroundAlexa‐Stratulat, T., Pešić, M., Gašparović, A. Č., Trougakos, I. P., & Riganti, C. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100643 · Cited by 81
Hypoxia as a Modulator of Inflammation and Immune Response in Cancer
Castillo‐Rodríguez, R. A., Trejo‐Solís, C., Cabrera‐Cano, A., Gómez‐Manzo, S., & Dávila‐Borja, V. M. (2022) · Cancers · doi:10.3390/cancers14092291 · Cited by 82
“For example, M2 TAMs secrete IL-6 with the corresponding expression of the IL-6 receptor in the tumoral cells, activating the STAT3 pathway to promote survival in the tumoral cells located in the hypoxic region [162].”
BackgroundInfluentialGuo, Y., Yu, T., Zhu, H., Xiao, Y., Guo, H., Shang, L., Zheng, W., Ma, S., Liu, X., & Bai, Y. (2020) · Cell Biology and Toxicology · doi:10.1007/s10565-020-09562-0 · Cited by 79
Huang, A., Sun, Z., Hong, H., Yang, Y., Chen, J., Gao, Z., & Gu, J. F. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05391-5 · Cited by 81
“Additionally, hypoxia and HIF accumulation have been found to be associated with resistance to chemotherapy as well as worse prognosis in patients with CRC [11–14].”
BackgroundHypoxia-Induced Phenotypes that Mediate Tumor Heterogeneity
Qian, J., & Rankin, E. B. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-12734-3_3 · Cited by 76
(2019) · Advances in Cancer Research · doi:10.1016/bs.acr.2018.11.001 · Cited by 71
TGF-β Modulated Pathways in Colorectal Cancer: New Potential Therapeutic Opportunities
Fasano, M., Pirozzi, M., Miceli, C. C., Cocule, M., Caraglia, M., Boccellino, M., Vitale, P., Falco, V. D., Farese, S., Zotta, A., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137400 · Cited by 69
“TGF-β expression has been linked to chemotherapy resistance in CRC. High levels of HIF-1 α /TGF-β 2 correlate with tumor relapse post-chemotherapy, indicating these factors as potential targets for overcoming chemo-resistance [135].”
BackgroundXu, G., Li, M., Wu, J., Qin, C., Tao, Y., & He, H. (2020) · Cancer Management and Research · doi:10.2147/cmar.s246272 · Cited by 69
“Additionally, it is suggested that hypoxic colorectal tumor microenvironment induced resistance to chemoresistance by activating the HIF-1α/transforming growth factor β2-mediated gliomaassociated oncogene protein-2 signaling.(34) In this research, we identified that HIF-1α was a downstream target gene of miR-138-5p.”
BackgroundLima, J. D. C. C., Simoes, E., de Castro, G. S., Morais, M., de Matos‐Neto, E. M., Alves, M. J., Neto, N. I. P., Figuerêdo, R. G., Zorn, T. M. T., Felipe-Silva, A., et al. (2019) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12441 · Cited by 67
“Tang et al. (2018) described that the HIF-1α/TGF-β activity is involved in resistance to therapy in colorectal cancer and proposed the analysis of this gene signature for predicting patient’s outcome, as an alternative clinical approach.28 We propose that further analysis of HIF1α/TGF-β pathways…”
BackgroundInfluentialSadrkhanloo, M., Paskeh, M. D. A., Hashemi, M., Raesi, R., Motahhary, M., Saghari, S., Sharifi, L., Bokaie, S., Mirzaei, S., Entezari, M., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114168 · Cited by 66
HIF1α promotes tumor chemoresistance via recruiting GDF15-producing TAMs in colorectal cancer
Zheng, H., Yu, S., Zhu, C., Guo, T., Liu, F., & Xu, Y. (2020) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.112394 · Cited by 65
The role of Hedgehog and Notch signaling pathway in cancer
Xia, R., Xu, M., Yang, J., & Ma, X. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00099-8 · Cited by 65
Cancer-Associated Fibroblasts: Implications for Cancer Therapy
Maia, A. R. R., & Wiemann, S. (2021) · Cancers · doi:10.3390/cancers13143526 · Cited by 64
“In colorectal cancer, it was shown that HIFα and TGFβ cooperate to induce hedgehog transcription factor GLI2 expression in tumourinitiating cancer cells, which drives stemness and chemoresistance [62].”
BackgroundRole of HIF-1α in the Responses of Tumors to Radiotherapy and Chemotherapy
Song, C. W., Kim, H., Kim, M.-S., Park, H. J., Paek, S.-H., Terezakis, S. A., & Cho, L. C. (2024) · Cancer Research and Treatment · doi:10.4143/crt.2024.255 · Cited by 65
“Likewise, hypoxia and HIF-1 α have been linked to increased chemoresistance [3,14,17-32].”
Yang, Z., Wang, W., Zhao, L., Wang, X., Gimple, R. C., Xu, L., Wang, Y., Rich, J. N., & Zhou, S. (2021) · Science Advances · doi:10.1126/sciadv.abb0737 · Cited by 60
“As cancer tissues are composed of both cancer cells and nonneoplastic cells (4, 5), the functions of these nonneoplastic cells are less well studied.”
BackgroundSelf-citationThe role of tumor microenvironment on cancer stem cell fate in solid tumors
Razi, S., Haghparast, A., Khameneh, S. C., Sadrabadi, A. E., Aziziyan, F., Bakhtiyari, M., Nabi‐Afjadi, M., Tarhriz, V., Jalili, A., & Zalpoor, H. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01129-w · Cited by 59
Mu, M., Zhang, Q., Li, J., Zhao, C., Li, X., Chen, Z., Sun, X., & Yu, J. (2023) · Cell Death and Differentiation · doi:10.1038/s41418-023-01228-8 · Cited by 57
Ervin, E.-H., French, R., Chang, C., & Pauklin, S. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.11.001 · Cited by 56
Comprehensive review of the resistance mechanisms of colorectal cancer classified by therapy type
Oh, J. M., Kim, S. W., Tsung, C., Kent, E. W., Jain, A., Ruff, S. M., & Zhang, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1571731 · Cited by 56
The tumor microenvironment: a key player in multidrug resistance in cancer
Meng, L., Zheng, Y., Liu, H., & Fan, D. (2024) · ONCOLOGIE · doi:10.1515/oncologie-2023-0459 · Cited by 56
Impact of KRAS mutation on the tumor microenvironment in colorectal cancer
Zhou, Y., Kuang, Y., Wang, C., Yu, Y., Pan, L., & Hu, X. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.88779 · Cited by 56
“The hypoxic TME promotes CRC cell stemness and resistance to chemotherapy; thus, this environment could be targeted to mitigate chemoresistance [123].”
BackgroundTakahashi, K., Akatsu, Y., Podyma‐Inoue, K. A., Matsumoto, T., Takahashi, H., Yoshimatsu, Y., Koinuma, D., Shirouzu, M., Miyazono, K., & Watabe, T. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.012492 · Cited by 56
Mao, X.-W., Nanzhang, Xiao, J., Wu, H., & Ding, K. (2021) · Journal of Immunology Research · doi:10.1155/2021/8887437 · Cited by 55
“According to recent literature, chemoresistance is largely due to expression and activation of HIF-1α [6].”
BackgroundHypoxia-driven angiogenesis and metabolic reprogramming in vascular tumors
Liu, L., Yu, J., Liu, Y., Xie, L., Hu, F., & Liu, H. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1572909 · Cited by 56
González-Ávila, G., Sommer, B., Flores‐Soto, E., & Aquino‐Gálvez, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316887 · Cited by 53
“CAFs secrete TGF β 2, which, together with HIF-1 α from the CRC cells, induced GLI2 expression without the canonical Hedgehog pathway participation [120].”
BackgroundXu, Y., Song, S., Wang, Z., & Ajani, J. A. (2019) · Cell Communication and Signaling · doi:10.1186/s12964-019-0479-3 · Cited by 53
Loh, J. J., & Ma, S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.727640 · Cited by 54
Tumor Microenvironment as a Therapeutic Target in Melanoma Treatment
Kharouf, N., Flanagan, T. W., Hassan, S.-Y., Shalaby, H., Khabaz, M., Hassan, S.-L., Megahed, M., Haïkel, Y., Santourlidis, S., & Hassan, M. (2023) · Cancers · doi:10.3390/cancers15123147 · Cited by 54
“CAFs can induce stemness properties of cancer cells via the activation of hypoxia-inducible factor (HIF-1α) and sonic hedgehog-GLI signaling [126,127].”
BackgroundAn overview of the role of interleukin-8 in colorectal cancer
Najdaghi, S., Razi, S., & Rezaei, N. (2020) · Cytokine · doi:10.1016/j.cyto.2020.155205 · Cited by 52
Role of the transforming growth factor‐β signaling pathway in the pathogenesis of colorectal cancer
Soleimani, A., Pashirzad, M., Avan, A., Ferns, G. A., Khazaei, M., & Hassanian, S. M. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28331 · Cited by 50
Intimate communications within the tumor microenvironment: stromal factors function as an orchestra
Cheng, B., Yu, Q., & Wang, W. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-022-00894-z · Cited by 50
“By developing patient-derived models to dissect the microenvironmental interaction between CAFs and tumor cells, we also described CAF-secreted TGF-β2, a member of the TGF-β family, inducing the expression of GLI Family Zinc Finger 2 (GLI2), an important effector of Hedgehog signaling, as a predominant pathway to prom…”
BackgroundSelf-citationThe emerging roles of Hedgehog signaling in tumor immune microenvironment
Wang, J., Cui, B., Li, X., Zhao, X., Huang, T., & Ding, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1171418 · Cited by 49
Ouyang, Q., Liu, Y., Tan, J., Li, J., Yang, D., Zeng, F., Huang, W., Kong, Y., Liu, Z., Zhou, H., et al. (2019) · PubMed · Cited by 47
Matsumoto, Y., Kudelka, M. R., Hanes, M. S., Lehoux, S. D., Dutta, S. M., Jones, M. B., Stackhouse, K. A., Cervoni, G. E., Heimburg‐Molinaro, J., Smith, D. F., et al. (2019) · Glycobiology · doi:10.1093/glycob/cwz095 · Cited by 47
“For example, TGFβ2 is associated with the hypoxic tumor microenvironment to promote cancer cell stemness and chemoresistance in colorectal carcinoma (Tang et al. 2018).”
BackgroundMessing Up the Cancer Stem Cell Chemoresistance Mechanisms Supported by Tumor Microenvironment
Gaggianesi, M., Franco, S. D., Pantina, V. D., Porcelli, G., D’Accardo, C., Verona, F., Veschi, V., Colarossi, L., Faldetta, N., Pistone, G., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.702642 · Cited by 49
STAT3 inhibition reduced PD‐L1 expression and enhanced antitumor immune responses
Jahangiri, A., Dadmanesh, M., & Ghorban, K. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29750 · Cited by 46
“Although several chemotherapeutic agents have been developed, unwanted toxicity effects to bone marrow, lungs, and gastrointestinal tract, and also new drug resistances, cause chemotherapy failures (Tang et al., 2018).”
BackgroundHedgehog Signaling in Colorectal Cancer: All in the Stroma?
Geyer, N., & Gerling, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031025 · Cited by 46
Lu, Y., Zhang, B., Wang, B., Wu, D., Wang, C., Gao, Y., Liang, W., Xi, H., Wang, X., & Chen, L. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-03093-w · Cited by 46
Marín, J. J. G., Macías, R. I. R., Monte, M. J., Herráez, E., Peleteiro‐Vigil, A., de Blas, B. S., Sanchon-Sanchez, P., Temprano, Á. G., Espinosa-Escudero, R. A., Lozano, E., et al. (2020) · Cancers · doi:10.3390/cancers12092605 · Cited by 44
Corgnac, S., Damei, I., Gros, G., Caidi, A., Terry, S., Chouaïb, S., Deloger, M., & Mami‐Chouaib, F. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004527 · Cited by 44
Hu, J., Lazar, A. J., Ingram, D. R., Wang, W., Zhang, W., Jia, Z., Ragoonanan, D. S., Wang, J., Xia, X., Mahadeo, K. M., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006991 · Cited by 43
Ma, M., Shi, Y.-H., Liu, Z., Zhu, Y., Zhao, G.-Y., Ye, J., Li, F.-X., Huang, X., Wang, X.-Y., Wang, J., et al. (2024) · Oncogene · doi:10.1038/s41388-024-03092-3 · Cited by 43
Interaction between Fibroblasts and Immune Cells Following DNA Damage Induced by Ionizing Radiation
Ragunathan, K., Upfold, N. L. E., & Oksenych, V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228635 · Cited by 45
Wu, N., Tu, Y., Fan, G., Ding, J., Luo, J., Wang, W., Zhang, C., Yuan, C., Zhang, H., Chen, P., et al. (2022) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2022.01.002 · Cited by 44
Javed, S. R., Skolariki, A., Zameer, M. Z., & Lord, S. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02833-1 · Cited by 42
Cancer Stem Cell for Tumor Therapy
Huang, B., Yan, X., & Li, Y. (2021) · Cancers · doi:10.3390/cancers13194814 · Cited by 42
Chen, Y., Yu, Z., Lv, M., Cai, Z., Zou, Y., Lan, P., Wu, X., & Gao, F. (2021) · Molecular Medicine · doi:10.1186/s10020-021-00402-3 · Cited by 43
Self-citation
Metadata
- Authors
- Tang, Y.-A., Chen, Y.-F., Bao, Y., Mahara, S., Yatim, S. M. J. M., Oguz, G., Lee, P. L., Feng, M., Cai, Y., Tan, E. Y., Fong, S. S., Yang, Z.-H., Lan, P., Wu, X.-J., & Yu, Q.
- Affiliations
- Agency for Science, Technology and Research (SG)
- Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou 510655, China;
- Jinan University (CN)
- Tan Tock Seng Hospital (SG)
- Sun Yat-sen University (CN)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2018-06-11
- Volume
- 115
- Issue
- 26
- Pages
- E5990-E5999
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC6042102
- OpenAlex
- W2808190774
- Cited by
- 277
- References
- 40
- Citations by year
- 2026: 18 · 2025: 25 · 2024: 34 · 2023: 50 · 2022: 38 · 2021: 48 · 2020: 34 · 2019: 24 · 2018: 6
- FWCI
- 10.60
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Hedgehog Signaling Pathway Studies
- Keywords
- colorectal cancer, chemoresistance, hypoxic tumor microenvironment, GLI2, HIF-1α, TGF-beta2, cancer stem cells, cancer-associated fibroblasts, Hedgehog signaling, cancer stemness, dedifferentiation, biomarkers, therapeutic target
- MeSH terms
- Zinc Finger Protein Gli2, Female, Fibroblasts, Humans, Male, Neoplasm Proteins, Nuclear Proteins, Colorectal Neoplasms, Cell Hypoxia, Gene Expression Regulation, Neoplastic, Drug Resistance, Neoplasm, Hypoxia-Inducible Factor 1, alpha Subunit, Transforming Growth Factor beta2, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.